Massive Bio links up with Inocras to genetically match cancer patients with clinical trials

Massive Bio has inked a deal to pair its advanced AI technology for clinical trial matching with Inocras' expertise in whole genome sequencing and bioinformatics to enhance personalised care for patients with cancer.

Inocras' chief of strategy officer Rebecca Jang believes the startup's "robust biomarker data will be further enriched by Massive Bio's capabilities, facilitating more precise patient matching with effective clinical trials," all within a single digital platform. Patients will also receive information about future clinical trials without requiring additional genetic tests.

Formerly known as Genome Insight, Inocras' technology identifies rare and complex mutations often overlooked by conventional genetic tests, such as standard panel sequencing or whole exome sequencing tests. The company recently introduced a user-friendly digital platform to streamline access to whole genome testing for cancer patients and their providers.

Meanwhile, Massive Bio's Synergy-AI platform analyses and summarises medical records, including biomarker data from multiple sources, to instantly match patients with over 14,000 clinical trials. According to the firm, its predictive analytics maximise trial enrollment potential and significantly reduce screen failures.

Last year, Massive Bio launched GPT-4-powered chatbots to expand access to cancer clinical trials.